|
May 15
|
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
|
|
May 14
|
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
|
|
May 10
|
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution"
|
|
May 8
|
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
|
|
May 7
|
Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should Know
|
|
May 6
|
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable
|
|
May 5
|
Earnings Beat: Castle Biosciences, Inc. (NASDAQ:CSTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
|
|
May 5
|
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript
|
|
May 3
|
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
|
|
May 2
|
Castle Biosciences Inc (CSTL) Q1 2024 Earnings: Surpasses Revenue Forecasts and Raises Annual ...
|
|
May 2
|
Castle Biosciences Reports First Quarter 2024 Results
|
|
Apr 30
|
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
|
|
Apr 17
|
We're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash Burn
|
|
Apr 11
|
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
|
|
Apr 10
|
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
|
|
Apr 10
|
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
|
|
Apr 5
|
What Makes Castle Bioscience (CSTL) a Prospective Investment?
|
|
Apr 4
|
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
|
|
Apr 2
|
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 27
|
Castle Biosciences Announces Updates to its Board of Directors
|